Skip to main content

Table 1 Demographic and tumour characteristics of older adults according to cancer site and dementia status

From: Patterns of staging, treatment, and mortality in gastric, colorectal, and lung cancer among older adults with and without preexisting dementia: a Japanese multicentre cohort study

 

Gastric cancer (n = 6016)

Colorectal cancer (n = 7257)

Lung cancer (n = 4502)

 

No dementia

Mild dementia

Moderate-to-severe dementia

No dementia

Mild dementia

Moderate-to-severe dementia

No dementia

Mild dementia

Moderate-to-severe dementia

Total

5712 (100)

224 (100)

80 (100)

6835 (100)

324 (100)

98 (100)

4213 (100)

216 (100)

73 (100)

Age, years

  65–69

1374 (24.1)

7 (3.1)

3 (3.8)

1796 (26.3)

11 (3.4)

5 (5.1)

1059 (25.1)

16 (7.4)

3 (4.1)

  70–74

1602 (28.0)

20 (8.9)

6 (7.5)

1921 (28.1)

39 (12.0)

6 (6.1)

1317 (31.3)

32 (14.8)

6 (8.2)

  75–79

1477 (25.9)

58 (25.9)

11 (13.8)

1666 (24.4)

70 (21.6)

24 (24.5)

1011 (24.0)

52 (24.1)

18 (24.7)

  80–84

865 (15.1)

77 (34.4)

23 (28.7)

984 (14.4)

107 (33.0)

28 (28.6)

600 (14.2)

62 (28.7)

15 (20.5)

  ≥ 85

394 (6.9)

62 (27.7)

37 (46.3)

468 (6.8)

97 (29.9)

35 (35.7)

226 (5.4)

54 (25.0)

31 (42.5)

Sex

  Male

4046 (70.8)

135 (60.3)

48 (60.0)

4044 (59.2)

175 (54.0)

38 (38.8)

2879 (68.3)

147 (68.1)

47 (64.4)

Comorbidity

  No comorbidity

4338 (75.9)

147 (65.6)

63 (78.8)

5493 (80.4)

238 (73.5)

75 (76.5)

2883 (68.4)

139 (64.4)

48 (65.8)

  Moderate comorbidities

1197 (21.0)

68 (30.4)

15 (18.8)

1190 (17.4)

69 (21.3)

22 (22.4)

1155 (27.4)

66 (30.6)

22 (30.1)

  Severe comorbidities

177 (3.1)

9 (4.0)

2 (2.5)

152 (2.2)

17 (5.2)

1 (1.0)

175 (4.2)

11 (5.1)

3 (4.1)

Cancer stage

  0

—

—

—

1853 (27.1)

55 (17.0)

8 (8.2)

8 (0.2)

0 (0.0)

0 (0.0)

  I

3608 (63.2)

115 (51.3)

33 (41.3)

1431 (20.9)

54 (16.7)

10 (10.2)

1397 (33.2)

53 (24.5)

7 (9.6)

  II

535 (9.4)

32 (14.3)

6 (7.5)

1326 (19.4)

75 (23.1)

30 (30.6)

392 (9.3)

11 (5.1)

3 (4.1)

  III

583 (10.2)

30 (13.4)

9 (11.3)

1339 (19.6)

71 (21.9)

20 (20.4)

791 (18.8)

30 (13.9)

13 (17.8)

  IV

908 (15.9)

40 (17.9)

21 (26.3)

843 (12.3)

57 (17.6)

24 (24.5)

1571 (37.3)

111 (51.4)

39 (53.4)

  Unstaged

78 (1.4)

7 (3.1)

11 (13.8)

43 (0.6)

12 (3.7)

6 (6.1)

54 (1.3)

11 (5.1)

11 (15.1)

Small cell lung cancer

  Yes

—

—

—

—

—

—

435 (10.3)

21 (9.7)

5 (6.8)

Tumour resectiona

  Yes

3868 (67.7)

146 (65.2)

26 (32.5)

4908 (71.8)

253 (78.1)

65 (66.3)

1354 (32.1)

33 (15.3)

5 (6.8)

Pharmacotherapy

  Yes

466 (8.2)

13 (5.8)

3 (3.8)

136 (2.0)

7 (2.2)

1 (1.0)

1091 (25.9)

37 (17.1)

9 (12.3)

Radiotherapy

  Yes

6 (0.1)

0 (0.0)

0 (0.0)

12 (0.2)

1 (0.3)

1 (1.0)

276 (6.6)

29 (13.4)

5 (6.8)

All-cause mortality within 3 years of cancer diagnosis

  Deaths

1773 (31.0)

133 (59.4)

67 (83.8)

1412 (20.7)

156 (48.1)

74 (75.5)

2371 (56.3)

184 (85.2)

71 (97.3)

Median follow-up period, years (IQR)

3.00 (1.99–3.00)

1.96 (0.37–3.00)

0.47 (0.16–1.94)

3.00 (3.00–3.00)

3.00 (0.89–3.00)

1.19 (0.25–2.88)

2.14 (0.69–3.00)

0.58 (0.16–1.78)

0.22 (0.08–0.58)

  1. Values are n (%) unless stated otherwise
  2. IQR interquartile range
  3. aTumour resection includes endoscopic resection, open surgical resection, laparoscopic resection, and thoracoscopic resection